Skip to main content
Top
Published in: Breast Cancer Research and Treatment 3/2010

01-06-2010 | Epidemiology

Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer

Authors: Sujee Jeon, Ji-Yeob Choi, Kyoung-Mu Lee, Sue K. Park, Keun-Young Yoo, Dong-Young Noh, Sei-Hyun Ahn, Daehee Kang

Published in: Breast Cancer Research and Treatment | Issue 3/2010

Login to get access

Abstract

Breast cancer development is related to genes regulating cell cycle progression such as CCND1, CDK7, and ESR1. We conducted a hospital-based case–control study to evaluate the role of genetic polymorphisms in these genes in breast cancer development among Korean women. Questionnaire data and samples were obtained from 864 incident breast cancer cases and 723 controls recruited from 1995 to 2002. Four single nucleotide polymorphisms (SNPs) in three genes were genotyped by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry [CCND1 Ex4-1G>A (rs9344), CDK7 Ex2-28C>T (rs2972388), ESR1 P325P Ex4-122G>C (rs1801132), and ESR1 T594T Ex8+229G>A (rs2228480)], and their associations with breast cancer risk were assessed. The odds ratios (ORs) and 95% confidence intervals (CIs) were estimated by unconditional logistic regression analysis adjusted for age, education, age at the first full-term pregnancy, and family history of breast cancer. Women carrying the CDK7 TT genotype had increased risk of breast cancer (OR, 1.4; 95% CI, 1.1–1.7). There was no significant association between breast cancer risk and the genetic polymorphisms of CCND1 and ESR1. However, when CDK7 and ESR1 P325P were combined, women carrying both the CDK7 TT and ESR1 P325P CC genotypes showed increased breast cancer risk (OR, 1.7; 95% CI, 1.1–2.5; P for trend, <0.01). In conclusion, our findings suggest that the combined genotypes of CDK7 and ESR1 are associated with breast cancer risk among Korean women.
Appendix
Available only for authorised users
Literature
1.
go back to reference Deshpande A, Sicinski P, Hinds PW (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24(17):2909–2915CrossRefPubMed Deshpande A, Sicinski P, Hinds PW (2005) Cyclins and cdks in development and cancer: a perspective. Oncogene 24(17):2909–2915CrossRefPubMed
2.
go back to reference Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6(5):369–381CrossRefPubMed Nakayama KI, Nakayama K (2006) Ubiquitin ligases: cell-cycle control and cancer. Nat Rev Cancer 6(5):369–381CrossRefPubMed
3.
go back to reference Wang J et al (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 106(2):273–280CrossRefPubMed Wang J et al (2007) Estrogen receptor alpha haplotypes and breast cancer risk in older Caucasian women. Breast Cancer Res Treat 106(2):273–280CrossRefPubMed
4.
go back to reference Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643CrossRefPubMed Musgrove EA, Sutherland RL (2009) Biological determinants of endocrine resistance in breast cancer. Nat Rev Cancer 9(9):631–643CrossRefPubMed
5.
go back to reference Shu XO et al (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14(1):91–97PubMed Shu XO et al (2005) Association of cyclin D1 genotype with breast cancer risk and survival. Cancer Epidemiol Biomarkers Prev 14(1):91–97PubMed
6.
go back to reference Bartkova J, Zemanova M, Bartek J (1996) Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer 66(6):732–737CrossRefPubMed Bartkova J, Zemanova M, Bartek J (1996) Expression of CDK7/CAK in normal and tumour cells of diverse histogenesis, cell-cycle position and differentiation. Int J Cancer 66(6):732–737CrossRefPubMed
7.
go back to reference Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153–166CrossRefPubMed Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9(3):153–166CrossRefPubMed
8.
go back to reference Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512CrossRefPubMed Sherr CJ, Roberts JM (1999) CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev 13(12):1501–1512CrossRefPubMed
9.
go back to reference Castro-Rivera E, Samudio I, Safe S (2001) Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276(33):30853–30861CrossRefPubMed Castro-Rivera E, Samudio I, Safe S (2001) Estrogen regulation of cyclin D1 gene expression in ZR-75 breast cancer cells involves multiple enhancer elements. J Biol Chem 276(33):30853–30861CrossRefPubMed
10.
go back to reference Lu C et al (2009) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116(3):571–575CrossRefPubMed Lu C et al (2009) CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis. Breast Cancer Res Treat 116(3):571–575CrossRefPubMed
11.
go back to reference Cortessis VK et al (2003) A case-control study of cyclin D1 CCND1 870A->G polymorphism and bladder cancer. Carcinogenesis 24(10):1645–1650CrossRefPubMed Cortessis VK et al (2003) A case-control study of cyclin D1 CCND1 870A->G polymorphism and bladder cancer. Carcinogenesis 24(10):1645–1650CrossRefPubMed
12.
go back to reference Wong YK et al (2003) Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 32(5):265–270PubMed Wong YK et al (2003) Cyclin D1 genotype in areca-associated oral squamous cell carcinoma. J Oral Pathol Med 32(5):265–270PubMed
13.
go back to reference Onay U et al (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8(1):6CrossRefPubMed Onay U et al (2008) Combined effect of CCND1 and COMT polymorphisms and increased breast cancer risk. BMC Cancer 8(1):6CrossRefPubMed
14.
go back to reference Tapper W et al (2008) The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 10(6):R108CrossRefPubMed Tapper W et al (2008) The influence of genetic variation in 30 selected genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res 10(6):R108CrossRefPubMed
15.
go back to reference Fernández LP et al (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 119(2):467–471CrossRefPubMed Fernández LP et al (2006) Estrogen and progesterone receptor gene polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer 119(2):467–471CrossRefPubMed
16.
go back to reference Einarsdottir K et al (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 10(1):R15CrossRefPubMed Einarsdottir K et al (2008) ESR1 and EGF genetic variation in relation to breast cancer risk and survival. Breast Cancer Res 10(1):R15CrossRefPubMed
17.
go back to reference Lee KM et al (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 11(12):4620–4626CrossRefPubMed Lee KM et al (2005) Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin Cancer Res 11(12):4620–4626CrossRefPubMed
18.
go back to reference Choi JY et al (2005) Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14(5):1090–1095CrossRefPubMed Choi JY et al (2005) Genetic polymorphisms of SULT1A1 and SULT1E1 and the risk and survival of breast cancer. Cancer Epidemiol Biomarkers Prev 14(5):1090–1095CrossRefPubMed
19.
go back to reference Yu CP et al (2008) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107(1):95–102CrossRefPubMed Yu CP et al (2008) Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1. Breast Cancer Res Treat 107(1):95–102CrossRefPubMed
20.
go back to reference Curran JE et al (2001) Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 95(4):271–275CrossRefPubMed Curran JE et al (2001) Association of estrogen receptor and glucocorticoid receptor gene polymorphisms with sporadic breast cancer. Int J Cancer 95(4):271–275CrossRefPubMed
21.
go back to reference Vasconcelos A et al (2002) Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J 8(4):226–229CrossRefPubMed Vasconcelos A et al (2002) Analysis of estrogen receptor polymorphism in codon 325 by PCR-SSCP in breast cancer: association with lymph node metastasis. Breast J 8(4):226–229CrossRefPubMed
22.
go back to reference Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76(3):260–263CrossRefPubMed Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76(3):260–263CrossRefPubMed
23.
go back to reference Larochelle S et al (2006) Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 13(1):55–62CrossRefPubMed Larochelle S et al (2006) Dichotomous but stringent substrate selection by the dual-function Cdk7 complex revealed by chemical genetics. Nat Struct Mol Biol 13(1):55–62CrossRefPubMed
24.
go back to reference Chen D et al (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921–4931CrossRefPubMed Chen D et al (2002) Phosphorylation of human estrogen receptor alpha at serine 118 by two distinct signal transduction pathways revealed by phosphorylation-specific antisera. Oncogene 21(32):4921–4931CrossRefPubMed
25.
go back to reference Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83(6):851–857CrossRefPubMed Beato M, Herrlich P, Schutz G (1995) Steroid hormone receptors: many actors in search of a plot. Cell 83(6):851–857CrossRefPubMed
Metadata
Title
Combined genetic effect of CDK7 and ESR1 polymorphisms on breast cancer
Authors
Sujee Jeon
Ji-Yeob Choi
Kyoung-Mu Lee
Sue K. Park
Keun-Young Yoo
Dong-Young Noh
Sei-Hyun Ahn
Daehee Kang
Publication date
01-06-2010
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 3/2010
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-009-0640-6

Other articles of this Issue 3/2010

Breast Cancer Research and Treatment 3/2010 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine